SENZA Stock Overview
SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SenzaGen AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr6.38 |
| 52 Week High | kr13.10 |
| 52 Week Low | kr5.46 |
| Beta | 0.38 |
| 1 Month Change | 2.90% |
| 3 Month Change | 0% |
| 1 Year Change | -37.45% |
| 3 Year Change | -56.00% |
| 5 Year Change | -80.06% |
| Change since IPO | -85.27% |
Recent News & Updates
Recent updates
We're Not Very Worried About SenzaGen's (STO:SENZA) Cash Burn Rate
Nov 28
We're Hopeful That SenzaGen (STO:SENZA) Will Use Its Cash Wisely
Jul 30Companies Like SenzaGen (STO:SENZA) Are In A Position To Invest In Growth
Apr 16Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation
Jan 01Shareholder Returns
| SENZA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.5% | 0.2% | 1.8% |
| 1Y | -37.5% | -4.3% | 10.7% |
Return vs Industry: SENZA underperformed the Swedish Biotechs industry which returned -5.1% over the past year.
Return vs Market: SENZA underperformed the Swedish Market which returned 7.8% over the past year.
Price Volatility
| SENZA volatility | |
|---|---|
| SENZA Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SENZA's share price has been volatile over the past 3 months.
Volatility Over Time: SENZA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 34 | Peter Nahlstedt | senzagen.com |
SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation, corrosion, sensitization, and absorption testing services, as well as phototoxicity services.
SenzaGen AB Fundamentals Summary
| SENZA fundamental statistics | |
|---|---|
| Market cap | kr154.32m |
| Earnings (TTM) | -kr22.10m |
| Revenue (TTM) | kr49.87m |
3.1x
P/S Ratio-7.0x
P/E RatioIs SENZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SENZA income statement (TTM) | |
|---|---|
| Revenue | kr49.87m |
| Cost of Revenue | kr14.94m |
| Gross Profit | kr34.93m |
| Other Expenses | kr57.03m |
| Earnings | -kr22.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 70.05% |
| Net Profit Margin | -44.31% |
| Debt/Equity Ratio | 2.5% |
How did SENZA perform over the long term?
See historical performance and comparison